About this, an interesting retrospective analysis showed that among EGFR-mutated NSCLC patients with high PD-L1 expression (TPS ≥50%) the efficacy of PD-1 inhibitors tended to be lower as compared to EGFR wild-type patients (38). Here, EGFR is linked to non-small cell lung carcinoma.